RUA Life Sciences Shares Rise After US Orders Returned to Pre-Covid-19 Levels
31 Agosto 2021 - 3:48AM
Noticias Dow Jones
By Jaime Llinares Taboada
Shares in RUA Life Sciences PLC rose Tuesday after it said that
order intake for U.S. supply has returned to pre-coronavirus levels
and that its vascular grafts business remains on track for FDA
approval in the first quarter of 2022.
The medical-devices group said indications from its major U.S.
supply customer suggest it is anticipating high-single-digit volume
growth over the coming year, and opportunities are being considered
regarding expanding the range of products supplied by RUA.
As for its vascular grafts division, the company said that it
has already solved the contamination issues identified in previous
testing. "The plan remains to have the scale up equipment fully
validated during the second quarter of 2022 thus allowing us to
meet growing demand for the grafts," RUA said.
Shares at 0810 GMT were up 10% at 140 pence.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
August 31, 2021 04:33 ET (08:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Rua Life Sciences (LSE:RUA)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Rua Life Sciences (LSE:RUA)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
